🟢 Novavax is trading 5.3% up today after XFG-adapted Nuvaxovid approvals in U.S., EU and Japan

Novavax is trading 5.3% up at $9.87 after partners received approvals for XFG-adapted Nuvaxovid in the United States, European Union, and Japan for the 2026–2027 vaccination season.

• Approvals preserve Novavax’s royalty opportunity while Sanofi and Takeda handle commercialization.
• Reuters also reported U.S. FDA approval of the updated Novavax-Sanofi vaccine, supporting the company-specific catalyst behind the gain.
• Broader markets are lower, making Novavax’s advance notably stronger than the prevailing risk-off tone.